Stockscreener 앱 받기
29.97
0.57%
0.17
시간 외 거래:
30.00
0.03
+0.10%
전일 마감가:
$29.80
열려 있는:
$30.02
하루 거래량:
519.63K
Relative Volume:
1.04
시가총액:
$1.84B
수익:
-
순이익/손실:
$-209.84M
주가수익비율:
-6.558
EPS:
-4.57
순현금흐름:
$-6.73M
1주 성능:
+15.22%
1개월 성능:
+42.65%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$29.05
$30.52
1주일 범위
$25.76
$30.75
52주 변동 폭
$16.50
$30.75
Damora Therapeutics Inc Stock (DMRA) Company Profile
명칭
Damora Therapeutics Inc
전화
(781) 281-9020
주소
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
29.97 | 1.83B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-24 | 개시 | RBC Capital Mkts | Outperform |
| 2026-03-25 | 개시 | Evercore ISI | Outperform |
| 2026-02-17 | 개시 | UBS | Buy |
| 2026-01-07 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Guggenheim | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | BofA Securities | Buy |
| 2020-11-23 | 개시 | Credit Suisse | Outperform |
| 2020-11-23 | 개시 | SVB Leerink | Outperform |
모두보기
Damora Therapeutics Inc 주식(DMRA)의 최신 뉴스
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Price to sales forward of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora awards 453,500 stock options to nine new hires - Stock Titan
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Index - marketscreener.com
Damora Therapeutics (DMRA) Is Up 6.2% After Broad Russell Index Additions Has The Bull Case Changed? - simplywall.st
Damora Therapeutics, Inc. Actuals & Estimates (NASDAQ:DMRA) - TradingView
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Value Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Damora Therapeutics, Inc.(NasdaqCM: DMRA) added to Russell 3000E Value Benchmark - marketscreener.com
Damora Therapeutics Rises as Traders Focus on Near-Term Pipeline Catalysts - Quiver Quantitative
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
DMRA Forecast — Price Target — Prediction for 2027 - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Form 144 Damora Therapeutics For: 22 June By Investing.com - Investing.com India
DMRA (NASDAQ: DMRA) Form 144 lists option-based sales to Maxim Group - Stock Titan
Damora Therapeutics (DMRA) Slips 0.89% as Stock Holds Above Key SupportOn Balance Volume - dars.gov.et
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Damora Therapeutics Announces Results of 2026 Annual Meeting - TipRanks
DMRA: All proposals passed, including director elections and auditor ratification, with strong shareholder support - TradingView
Damora Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Guggenheim Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Costs WeighEBITDA Margin Trends - newsline.com
DMRA Reiterates by Wedbush -- Price Target Maintained at $35 - GuruFocus
DMRA Initiated Coverage by HC Wainwright & Co. -- Price Target S - GuruFocus
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Damora Therapeutics Inc (DMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Damora Therapeutics Inc 주식 (DMRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bruno Julianne | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
129,000 |
0 |
137,032 |
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
1.18%
2.48%
자본화:
|
볼륨(24시간):